Page last updated: 2024-12-04

2,4-diaminobutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-diaminobutyric acid: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,4-diaminobutyric acid : A diamino acid that is butyric acid in which a hydrogen at position 2 and a hydrogen at position 4 are replaced by amino groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID470
CHEMBL ID307931
CHEBI ID64307
SCHEMBL ID34705
MeSH IDM0047863

Synonyms (52)

Synonym
CHEMBL307931 ,
dl-2,4-diaminobutyric acid
chebi:64307 ,
NSC41117 ,
NCI60_003932
alpha,gamma-diaminobutyric acid
2,4-diaminobutyric acid
einecs 206-166-2
butanoic acid, 2,4-diamino-
butyric acid, 2,4-diamino-
2,4-diaminobutanoic acid
6970-28-1
17E1DD55-BA23-4412-A558-FD4BB42055F1
305-62-4
2,4-diamino-butyric acid
LMFA01100052
2,4-diamino-butanoic acid
AKOS006220721
92v7km11zk ,
unii-92v7km11zk
alpha,gamma-diaminobutanoic acid
FT-0638649
FT-0633825
AM82466
SCHEMBL34705
J-501041
2,4-diamino-butyricacid
2,4-diaminobutanoic acid #
.alpha.,.gamma.-diaminobutyric acid
dl-.alpha.,.gamma.-diaminobutyric acid
(rs)-2,4-diaminobutyric acid
2,4-diaminobutyric acid, dl-
dl-2,4-diamino-n-butyric acid
dl-daba
mfcd00025612
dl-2,4-diamino-n-butyric acid (h-dl-dab-oh)
butanoic acid, 2,4-diamino-, (+)-
dl-2,4-diaminobutanoic acid
2,4-diamino-n-butyric acid
2,4-diamino-butanoate
dl-2,4-diaminobutanoate
dl-alpha,gamma-diaminobutyric acid
A847258
DTXSID80862749
Q27895750
FT-0700566
bdbm50226144
(s)-n-[ pound 4,5-dimethoxybenzocyclobut-1-yl pound(c)methyl ]-n-methylamine hydrochloride155
2,4-diaminobutanoicacid
rac-2,4-diaminobutyricacid-d5dihydrochloride
PD094218
EN300-97504
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
diamino acidAny amino acid carrying two amino groups.
gamma-amino acidA non-proteinogenic amino-acid in which the amino group is located on the carbon atom at the position gamma to the carboxy group.
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.507510.0000AID71434
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.507510.0000AID71434
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.507510.0000AID71434
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.505710.0000AID71434
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.497310.0000AID71434
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.507510.0000AID71434
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.498810.0000AID71434
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.504610.0000AID71434
Sodium- and chloride-dependent GABA transporter 1Rattus norvegicus (Norway rat)IC50 (µMol)2.00000.00132.22068.3000AID205301
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.507510.0000AID71434
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.507510.0000AID71434
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.507510.0000AID71434
Sodium- and chloride-dependent GABA transporter 2Rattus norvegicus (Norway rat)IC50 (µMol)2.00000.00321.79008.3000AID205301
Sodium- and chloride-dependent GABA transporter 3Rattus norvegicus (Norway rat)IC50 (µMol)2.00000.00321.54318.3000AID205301
Sodium- and chloride-dependent betaine transporterRattus norvegicus (Norway rat)IC50 (µMol)2.00000.00321.54318.3000AID205301
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.506510.0000AID71434
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.505710.0000AID71434
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.507510.0000AID71434
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.507510.0000AID71434
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)0.03300.00010.507510.0000AID71434
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID71434In vitro inhibition of [3H]GABA binding to Gamma-aminobutyric acid receptor from rat brain synaptic membranes.1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions.
AID450158Inhibition of alpha-dicarbonyls-induced advanced glycation end product formation assessed as protection against 50 eq. MG-induced insulin degradation at 3.75 mM after 24 hrs by RP-HPLC2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
AID26119pKa value of the compound1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions.
AID205301In vitro inhibition of rat neuronal (synaptosomal) GABA uptake.1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (144)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (28.47)18.7374
1990's20 (13.89)18.2507
2000's32 (22.22)29.6817
2010's44 (30.56)24.3611
2020's7 (4.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.26 (24.57)
Research Supply Index5.06 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index28.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.64%)5.53%
Reviews2 (1.28%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other153 (98.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]